Member Info for sightwatcher

Confirmed: Sussex-based IosBio has found a way to turn injected vaccines into tablets and signed a deal with California's ImmunityBio. N4 Pharma better speed up the process to find a partner at least in Europe to speedy development leading to trials.

Patents are beginning and we have to wait for any partner to comes along to implement Nuvec in vaccines otherwise it will be sitting idle on research desks.

Patent is foundation building block for new idea and approval is first phase. Unless this new idea is manufactured, marketed and implemented, revenues won’t be generated and hence the value

Agreed bidnolid: These are patents: they are basis of future revenues when actual product is manufactured and marketed!
And N4Pharma will need collaboration with big Pharma.If in the eyes of large Phamecutical Company Nuvec is money spinner then it will be taken over. We should live on hope that Nuvec will be not sitting idle on research desks.

Good patent news granted in Europe. ASAP US,China and India is on the list , then company will be ripe for to be taken over to speed up Nuvec of its implementation in delivery of vaccination

Fugazi1: definitely not 250P next week but not 140’s either!

Fugazi1: you are day dreaming , it won’t fall back to mid 140 , you have missed the boat unless market takes a turn in October which is sometimes proves to be market crash month.

Agreed mazik: sit tight and be patient and you never know it will earn us a huge reward. It is bit of a curiosity that why any large Pharma has not grabbed this little company which is so cheap even with paying a hefty premium but will be money spinner.

Bigun2: very good thought , we will be very happy if someone comes with a offer of over a pound! It is a good concept and very practical too but it is amazing, why big Pharma hasn’t come with a offer and to speed up the process and implement Nuvec in vaccination.

Don’t bet on it when MED 3000 gets FDA approval and it won’t yield anything as in Europe of its approval. You needed large Pharma to manufacture and marketing of the product and in the absence of it we are all doomed.

It will be as usual full of empty , hollow and misleading promises, nothing sensational will be in the results apart from drum beating of trial and approval in US.What they have achieved nothing really after excited approval of MED 3000 in Europe.

Thanks MayAnya:?their PR is poor because they are not confident yet that Nuvec will be employed successfully one day

Hall123: it looks very good on slides and let us hope they will be successful Implementing Nuvec practically in vaccination but it will take quite while though and may be not in the near future
because SP speak itself:

Fugazi1: you are very desperate and very eager to get market melting down so you can get entry at £ mark but it is day dreaming , it won’t happen though.

Fugazi1: You are predicting October Meltdown! Which nobody knows and if that happens , it will be everywhere and everything!

Agreed Liambooth. The product MED 3000 is proving to be good sitting on Futura Office desks and after approval from EU , they cannot find any large Pharma to market in EU.

Agreed Liambooth: The product won’t sell
in the absence of collaboration with any big Pharma because marketing is time consuming and very expensive , only Large Pharma can do it to yield any results. It looks the product will be sitting idle on Futura office’s tables.After getting approval from EU, they are unable to find any collaboration with any large Pharma so hence product MED 3000 is failure and will be failure .

The price speaks itself and market believes
although product works up to certain degree but it won’t yield any thing and let us hope market is proven to be wrong.

Agreed Liambooth, I think we have lost money who have bought at peak. There doesn’t seem any way they will make any profit at all.

Agreed! There might be possibility of shorts being closed.